CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.

Waters, J Dawn; Sanchez, Carlos; Sahin, Ayguen; Futalan, Diahnn; Gonda, David D; Scheer, Justin K; Akers, Johnny; Palanichamy, Kamalakannan; Waterman, Peter; Chakravarti, Arnab; Weissleder, Ralph; Morse, Brent; Marsh, Nick; Furfine, Eric; Chen, Clark C; Carvajal, Irvith; Carter, Bob S

Waters, J Dawn; Sanchez, Carlos; Sahin, Ayguen; Futalan, Diahnn; Gonda, David D; Scheer, Justin K; Akers, Johnny; Palanichamy, Kamalakannan; Waterman, Peter; Chakravarti, Arnab; Weissleder, Ralph; Morse, Brent; Marsh, Nick; Furfine, Eric; Chen, Clark C; Carvajal, Irvith; Carter, Bob S.

Affiliation

Waters JD; Division of Neurosurgery, University of California-San Diego, La Jolla, CA 92093, USA. j.dawn.waters@gmail.com

J Neurooncol ; 110(1): 37-48, 2012 Oct.

Article in En | MEDLINE | ID: mdl-22875706

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/pharmacology; Brain Neoplasms/therapy; Chemoradiotherapy/methods; Fibronectins/pharmacology; Glioma/therapy; Peptide Fragments/pharmacology; Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors; Animals; Brain Neoplasms/pathology; Cell Line, Tumor; Dacarbazine/administration & dosage; Dacarbazine/analogs & derivatives; Glioma/pathology; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Temozolomide; Xenograft Model Antitumor Assays

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Peptide Fragments / Brain Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Fibronectins / Vascular Endothelial Growth Factor Receptor-2 / Chemoradiotherapy / Glioma Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Year: 2012 Type: Article

Fulltext

XML

PubMed Links

Search on Google